Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyra Therapeutics

8.55
+0.02000.23%
Post-market: 8.790.2400+2.81%16:41 EDT
Volume:33.33K
Turnover:282.11K
Market Cap:13.67M
PE:-0.14
High:8.56
Open:8.56
Low:8.29
Close:8.53
Loading ...

Lyra Therapeutics Inc. CFO Jason Cavalier Reports Disposal of Common Shares

Reuters
·
15 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, TC Energy, Cancer test makers

Reuters
·
28 Jun

Lyra Therapeutics Secures $4.3M in Direct Offering

TIPRANKS
·
27 Jun

BUZZ-Lyra Therapeutics falls after direct stock deal, private placement

Reuters
·
27 Jun

BRIEF-Lyra Therapeutics Announces $15M Direct Offering and Private Placement Priced At-Market Under Nasdaq Rules

Reuters
·
27 Jun

Lyra Therapeutics Inc - Combined Effective Purchase Price per Share Is $11.81

THOMSON REUTERS
·
27 Jun

Lyra Therapeutics Announces up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
27 Jun

Lyra Therapeutics Regains Nasdaq Compliance in June 2025

TIPRANKS
·
24 Jun

Lyra Therapeutics Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
10 Jun

Refile-Lyra Therapeutics, Inc. : H.c. Wainwright Adjusts Target Price to $16 From $2 to Reflect 1-for-50 Reverse Stock Split (Clarifies PT Is Split Adjusted)

THOMSON REUTERS
·
10 Jun

Lyra Therapeutics target adjusted to $16 from $2 at H.C. Wainwright

TIPRANKS
·
10 Jun

Lyra Therapeutics Unveils Strategic Plans for LYR-210

TIPRANKS
·
09 Jun

Jefferies Sticks to Their Hold Rating for Lyra Therapeutics (LYRA)

TIPRANKS
·
04 Jun

BTIG Keeps Their Hold Rating on Lyra Therapeutics (LYRA)

TIPRANKS
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
02 Jun

Lyra Therapeutics Inc : Jefferies Raises Target Price to $30 From $0.50

THOMSON REUTERS
·
02 Jun

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Benzinga
·
02 Jun

BUZZ-Lyra Therapeutics soars after nasal drug meets trial goals in late-stage study

Reuters
·
02 Jun

Lyra Therapeutics Shares Soar 603% to $34.67 After Rhinosinusitis Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
02 Jun